A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
I8F-MC-GPIL - ClinicalTrials.gov - NCT05706506
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide/(GIP/GLP-1 RA agonist) in participants with type 2 diabetes (T2D).
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Type 2 diabetesWhat the trial is testing?
LY3298176Could I receive a Placebo?
NoEnrollment Goal
152Trial Dates
Mar 8, 2023 - Oct 31, 2023How long will I be in the trial?
The study will last approximately 15 weeks and up to 6 visits.Trial Phase
IVKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have Type 2 diabetes
Must be overweight
Not be taking diabetes medications 3 months before entering the study
Participants Must Not:
Have Type 1 diabetes
Have history of diabetic eye diseases
Have heart disease or stroke
Have had an episode of ketoacidosis
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo